Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.
作者信息
Taylor Shawn R, Moody Michayla T
机构信息
Wingate University, Hendersonville Campus, Hendersonville, NC, USA.
Dale Fell Health Center, Appalachian Mountain Community Health Center, Asheville, NC, USA.
出版信息
J Pharm Technol. 2018 Oct;34(5):231-232. doi: 10.1177/8755122518782155. Epub 2018 Jun 25.
Abstract
摘要
相似文献
1
Acute Kidney Injury Occurring in a Patient Initiated on Dulaglutide.在开始使用度拉糖肽的患者中发生的急性肾损伤。
J Pharm Technol. 2018 Oct;34(5):231-232. doi: 10.1177/8755122518782155. Epub 2018 Jun 25.
2
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.每周一次度拉糖肽在2型糖尿病患者II期和III期临床试验中对肾功能的影响。
Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.
3
Patient Reported Outcomes following initiation of Glucagon-like peptide-1 Receptor agonists in patients with type 2 Diabetes in a specialist endocrinology practice of the LMC diabetes registry: The PROGRESS-Diabetes study.在 LMC 糖尿病注册中心的内分泌专科实践中，观察 2 型糖尿病患者起始使用胰高血糖素样肽-1 受体激动剂后的患者报告结局：PROGRESS-Diabetes 研究。
Diabetes Res Clin Pract. 2019 Oct;156:107820. doi: 10.1016/j.diabres.2019.107820. Epub 2019 Aug 22.
4
Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes Mellitus: Data from a Real-World Study in Spain.2型糖尿病中胰高血糖素样肽1受体激动剂：来自西班牙一项真实世界研究的数据。
Diabetes Ther. 2021 May;12(5):1535-1551. doi: 10.1007/s13300-021-01039-5. Epub 2021 Apr 16.
5
Pancreatic safety in Japanese patients with type 2 diabetes treated with once weekly dulaglutide 0.75 mg up to 52 weeks in phase 3 clinical trials.在3期临床试验中，日本2型糖尿病患者接受每周一次0.75毫克度拉鲁肽治疗长达52周的胰腺安全性。
Endocr J. 2017 Feb 27;64(2):191-206. doi: 10.1507/endocrj.EJ16-0365. Epub 2016 Nov 15.
6
Clinical Efficacy and Parameters Affecting the Response to Dulaglutide Treatment in Patients with Type 2 Diabetes: A Retrospective, Real-World Data Study.度拉糖肽治疗2型糖尿病患者的临床疗效及影响治疗反应的参数：一项回顾性真实世界数据研究
Diabetes Ther. 2019 Aug;10(4):1453-1463. doi: 10.1007/s13300-019-0658-7. Epub 2019 Jun 25.
7
Assessment of Pancreas Safety in the Development Program of Once-Weekly GLP-1 Receptor Agonist Dulaglutide.度拉糖肽每周 1 次给药开发计划中胰腺安全性评估。
Diabetes Care. 2017 May;40(5):647-654. doi: 10.2337/dc16-0984. Epub 2017 Mar 10.
8
Dulaglutide and Insulin: How Can the AWARD Studies Help Guide Clinical Practice?度拉糖肽与胰岛素：AWARD研究如何助力指导临床实践？
Diabetes Ther. 2020 Aug;11(8):1627-1638. doi: 10.1007/s13300-020-00863-5. Epub 2020 Jun 20.
9
Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.法国2型糖尿病患者中GLP-1受体激动剂治疗模式及持续性：一项回顾性队列分析
Diabetes Ther. 2021 May;12(5):1553-1567. doi: 10.1007/s13300-021-01055-5. Epub 2021 Apr 17.
10
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).度拉糖肽对 2 型糖尿病合并非酒精性脂肪性肝病患者肝脂肪的影响：随机对照试验（D-LIFT 试验）。
Diabetologia. 2020 Nov;63(11):2434-2445. doi: 10.1007/s00125-020-05265-7. Epub 2020 Aug 31.
引用本文的文献
1
Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors vs glucagon-like peptide 1 receptor agonists in elderly patients with type 2 diabetes mellitus: a meta-analysis.钠-葡萄糖协同转运蛋白2抑制剂与胰高血糖素样肽1受体激动剂在老年2型糖尿病患者中的疗效和安全性比较：一项荟萃分析。
Front Endocrinol (Lausanne). 2025 Aug 26;16:1486655. doi: 10.3389/fendo.2025.1486655. eCollection 2025.
2
The Beneficial Effects of GLP-1 Receptor Agonists Other than Their Anti-Diabetic and Anti-Obesity Properties.胰高血糖素样肽-1受体激动剂除抗糖尿病和抗肥胖特性之外的有益作用。
Medicina (Kaunas). 2024 Dec 26;61(1):17. doi: 10.3390/medicina61010017.
3
Semaglutide-associated kidney injury.司美格鲁肽相关的肾损伤。
Clin Kidney J. 2024 Aug 13;17(9):sfae250. doi: 10.1093/ckj/sfae250. eCollection 2024 Sep.
4
Can glucagon-like peptide-1 receptor agonists cause acute kidney injury? An analytical study based on post-marketing approval pharmacovigilance data.胰高血糖素样肽-1 受体激动剂会引起急性肾损伤吗？基于上市后药物警戒监测数据的分析研究。
Front Endocrinol (Lausanne). 2022 Dec 13;13:1032199. doi: 10.3389/fendo.2022.1032199. eCollection 2022.
5
A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist.一例使用另一种胰高血糖素样肽-1（GLP-1）受体激动剂多年治疗后出现度拉糖肽诱导的急性间质性肾炎的病例。
Clin Diabetes. 2022 Fall;40(4):508-510. doi: 10.2337/cd21-0142.
本文引用的文献
1
Effects of once-weekly dulaglutide on kidney function in patients with type 2 diabetes in phase II and III clinical trials.每周一次度拉糖肽在2型糖尿病患者II期和III期临床试验中对肾功能的影响。
Diabetes Obes Metab. 2017 Mar;19(3):436-441. doi: 10.1111/dom.12816. Epub 2016 Nov 24.
2
Acute tubulointerstitial nephritis following treatment with exenatide.接受 exenatide 治疗后发生的急性肾小管间质性肾炎。
Diabet Med. 2013 Jan;30(1):123-5. doi: 10.1111/j.1464-5491.2012.03738.x.
3
Liraglutide-induced acute kidney injury.利拉鲁肽引起的急性肾损伤。
Pharmacotherapy. 2012 Jan;32(1):e7-11. doi: 10.1002/PHAR.1014.
4
Exenatide-associated ischemic renal failure.艾塞那肽相关性缺血性肾衰竭。
Diabetes Care. 2009 Feb;32(2):e22-3. doi: 10.2337/dc08-1309.
5
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.
Zotero 插件